BioSpace News Archive

Paragon 28, Inc. announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,206,000 additional shares, at a public offering price of $16.00 per share.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 340,000 shares of its common stock to nine employees outside Fusion’s 2020 Stock Option and Incentive Plan.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (“ASCO”) Plenary Series Session on February 6, 2024.

icotec ag is pleased to announce the appointment of Christoph Eigenmann as its new CEO for the United States.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 33,750 restricted stock units of Arcutis’ common stock to five newly hired employees.

Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that Mark Rothera, its President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to seven new employees, in each case with a grant date of February 1, 2024, as equity inducement awards under the terms of the company’s 2023 Inducement Plan.

Precigen, Inc. (Nasdaq: PGEN) today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.